Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) will report its Q4 and full-year 2020 financial results on March 11, 2021, after U.S. market close. Management will host a conference call at 4:30 p.m. ET to discuss these results and recent company highlights. Nabriva is focused on anti-infective agents, with FDA approval for XENLETA® for community-acquired bacterial pneumonia and developing CONTEPO™ for complicated urinary tract infections. Interest will be on financial performance and commercial potential of its products.

Positive

• FDA approval for XENLETA® enhances market position.
• Development of CONTEPO™ offers potential for market expansion.

Negative

• Uncertainty of market demand for XENLETA.
• Risks associated with clinical trial outcomes and regulatory approvals.

DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2020 financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, March 11, 2021. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 for international participants, with Conference ID #2689459. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com. A replay will be available on this website shortly after conclusion of the event for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully implement its commercialization plans for XENLETA and whether market demand for XENLETA is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for XENLETA, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
IR@Nabriva.com

For Media
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502

FAQ

When will Nabriva report its Q4 2020 results?

Nabriva will report its Q4 2020 financial results on March 11, 2021.

What time is the conference call for Nabriva's financial results?

The conference call is scheduled for 4:30 p.m. ET on March 11, 2021.

What products does Nabriva Therapeutics focus on?

Nabriva specializes in anti-infective agents such as XENLETA® and CONTEPO™.

What is the significance of Nabriva's FDA approval for XENLETA®?

The FDA approval for XENLETA® allows Nabriva to compete in the market for community-acquired bacterial pneumonia.

What are the risks mentioned in Nabriva's press release?

Risks include uncertainties in market demand and potential issues with clinical trial outcomes and regulatory approvals.